Abstract 2854
Background
Uveal melanoma (UM) is the most common intraocular malignancy. The disease is clinically and genetically distinct from cutaneous melanoma and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in metastatic UM patients, we analysed the real-world outcomes in a nationwide population-based study.
Methods
Clinical data on patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of all Danish patients with metastatic melanoma. Diagnosis of primary UM was confirmed via the Copenhagen Epidemiological Uveal Melanoma Study database. Survival before (2011-2013, pre-ICI; n = 32) and after (2014-2018, post-ICI; n = 94) the approval of first-line treatment with ICI was analysed.
Results
Treatment and survival data were available from 126 metastatic UM patients. First-line treatment consisted of temozolomide in 28, ipilimumab in 24, pembrolizumab in 43 and the combination ipilimumab/nivolumab in 19 patients. Twelve patients did not receive any systemic treatment. No complete responses were observed. A partial response was observed in 7.0% of patients treated with pembrolizumab and in 21.1% treated with ipilimumab plus nivolumab. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.7 months in the post-ICI era (HR 0.37; 95 CI 0.24-0.59; p < 0.01). The estimated 1-year overall survival rate increased from 25.0% to 41.9% and the median overall survival improved from 7.8 months to 10.0 months, respectively (HR 0.52; 95 CI 0.34-0.80; p < 0.01).
Conclusions
The introduction of ICI as first-line treatment appears to have significantly improved the real-world survival of patients with metastatic UM, despite relatively low response rates. With the lack of therapies proven effective in randomized trials, these data support the current treatment with ICI in patients with metastatic UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Danish Melanoma Oncology Group.
Funding
The Danish Metastatic Melanoma database is supported by BMS, Roche, MSD and Novartis. K.F. Bol has received funding from the European Union (Marie Sklodowska-Curie grant).
Disclosure
K.F. Bol: Travel / Accommodation / Expenses: Roche. E. Ellebaek: Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Kyowa Kirin. M. Donia: Honoraria (self): BMS; Honoraria (self): Sanofi-Genzyme; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Novartis. H. Schmidt: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis. L. Bastholt: Advisory / Consultancy: MSD; Advisory / Consultancy: Incyte; Advisory / Consultancy: BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: Eisai; Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Amgen; Advisory / Consultancy: Swedish Orphan. I. Svane: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Incyte; Honoraria (self), Advisory / Consultancy: TILT Bio; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): BMS; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Shareholder / Stockholder / Stock options: IO Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract